【国泰海通美护】四环医药 26H1 earnings preannouncement

English summary

The company issued a profit preannouncement: for 26H1, the company recorded revenue of no less than RMB 1.14 billion, roughly flat year-on-year; net profit for the period of no less than RMB 210 million, up no less than 217.2% year-on-year. The significant profit growth was mainly driven by the steady development of the medical aesthetics business, the commercialization of innovative drugs, increased investment income from external investments, and optimized asset structure. Among them, the medical aesthetics business recorded revenue of no less than RMB 680 million in the period, up no less than 16.1% year-on-year; segment profit of no less than RMB 320 million, continuing to be an important source of profit for the group. Core product 乐提葆 (botulinum toxin) maintained steady growth, while regenerative aesthetic products (including 童颜针 and 少女针) and functional aesthetic products continued to ramp up. The innovative drug business saw good progress in commercialization and internationalization of multiple approved products, with consolidated revenue growing significantly and losses significantly narrowed. Due to the successful IPO of an invested project by a joint venture and associate, the group recognized investment income of no less than RMB 110 million in the period; …